Give up on biosimilars? Never!
One drug class is delivering millions in cost savings for Prime's Blue Plan clients
February 20, 2020
I feel like I should be passing out cigars.
Based on recommendations Prime made in its Medical Business Committee (formerly known as the Specialty Drug Strategy Committee) meeting in September 2018, Prime’s Blue Plan clients are starting to save millions of dollars with biosimilars. And there’s more to come.
It’s been a long road to get here
For a host of complex reasons, the United States market has resisted the financial relief biosimilars have been delivering in Europe.1,2 Europe has approved 43 biosimilars; the U.S. Food and Drug Administration (FDA) has approved just 26 of them. Of that 26, only 13 are now marketed in the U.S.
How are Prime and its Blue Plans saving money with biosimilars now? What’s changed?
Of the 13 biosimilars launched in the U.S., five treat neutropenia, a condition that’s often a side effect from cancer. Those five biosimilars are granulocyte-colony stimulating factor (G-CSF) drugs; they emulate the body’s own G-CSF to help patients with cancer replace white blood cells depleted by chemotherapy.
Drugs that treat neutropenia
Of those five G-CSF drugs, four were just launched in 2018 and 2019. That makes for big changes in one drug class. That causes downward pricing pressure for all the drugs in the class.
Patient turnover based on the condition: More than 11,000 patients with cancer develop neutropenia every year. Most patients that need treatment for neutropenia only take G-CSF drugs for about six months. That means the pool of patients is constantly renewing.
Preferring biosimilars brings home the biggest savings
Following the September 2018 recommendation from Prime’s MBC meeting, three Blue Plans changed their medical policies. Their medical policies preferred the biosimilars over the reference drug in the G-CSF class, starting in the first half of 2019. Prime’s other Blue Plan clients added biosimilars to their formularies but made the selection neutral.
By year-end 2019, the formulary-neutral Blue Plans saw biosimilar conversions at about 18 percent. But the three Blue Plans who took an active management approach preferring biosimilars saw high conversion rates of 70 percent, 73 percent and 97 percent. Collectively, this delivered a cost savings of $4 million.
Implementation of G-CSF preferred biosimilar strategy for three Blue Plan clients in 2019
Share of biosimilars by Blue Plan following first year implementation
We presented these findings to Prime’s December MBC meeting. Needless to say, the Blue Plans who actively preferred biosimilars on their formularies were proud to help us present these findings.
If all Prime’s Blue Plan clients prefer biosimilars in the G-CSF space, we project savings of $41 to $55 million a year.
If all Prime’s Blue Plan clients prefer biosimilars in the G-CSF space, we project savings of $41 to 55 million a year. Let’s do it again.
Two other opportunities exist to capitalize on biosimilars in the oncology space.
Trastuzumab (Herceptin®) now has biosimilars approved and launched that treat breast or gastric cancer. If Prime’s Blue Plan clients prefer these biosimilars, estimated savings could total $31 million over two years.
Bevacizumab (Avastin®) now has biosimilars approved and launched that treats colon, rectal or breast cancer. If Prime’s Blue Plan clients prefer these biosimilars, estimated savings could total $23 million over two years. Savings from preferring biosimilars of trastuzumab and bevacizumab could total $52 million over two years.
Prime’s MBC meetings put Prime’s Blue Plan clients on top of the latest opportunities.
The MBC is a truly unique aspect of Prime’s total drug management approach. This quarterly meeting brings clients together with experts from Prime’s clinical, formulary, health outcomes and specialty teams. Clients bring their market-specific insights and perspective.
Together, we engage in decision-making for the specialty drugs that have such a big impact on medical spend. Together, we shape drug management strategies for the future, achieving savings to help keep these life-changing and costly drugs available to members.
- Education and strategy are key to nurturing biosimilars for success, FiercePharma. Jan 12, 2020. Accessed at: https://www.fiercepharma.com/pharma/education-and-strategy-are-key-to-nurturing-biosimilars-for-success
- Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan, July 18, 2018. FDA.gov. Accessed at: https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas
January 18, 2022
The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab)…
December 14, 2021
Rituxan® (rituximab) from Genentech was first approved by the FDA in 1997 for…
December 7, 2021
Herceptin® (trastuzumab) from Genentech is a targeted cancer drug used primarily to treat…